Liposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections: Evaluation of United Kingdom Compassionate Use Data

Archives of Internal Medicine

Volumn 155, Issue 10, 1995, Pages 1093-1098

  Ng, Tony T C ^a   Denning, David W ^a,b  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; DRUG CARRIER; LIPOSOME; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; POTASSIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; CANDIDIASIS; CHILD; CLINICAL TRIAL; HUMAN; MULTICENTER STUDY; MYCOSIS; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FUNGAL MENINGITIS; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MUCORMYCOSIS; PRIORITY JOURNAL; RIGOR;

ADOLESCENT; ADULT; AGED; AMPHOTERICIN B; ASPERGILLOSIS; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; DRUG CARRIERS; HUMAN; LIPOSOMES; MIDDLE AGE; MYCOSES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0028988695     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1995.00430100129015     Document Type: Article

References (20)

1. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2121 published cases. Rev Infect Dis. 1990;12:1147-1201.
2. Christiansen KJ, Bernard EM, Gold JWM, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152:1037-1043.
3. Zoubek A, Emminger W, Emminger-Schmidmeier W, et al. Conventional vs liposomal amphotericin B in immunosuppressed children. Pediatr Hematol Oncol. 1992;9:187-190.
4. Lopez-Berestein G, Rosenblum MG, Mehta R. Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Delivery. 1984;1:199-206.
5. Proffitt RT, Satorius A, Chiang SM, Sullivan L, Adler-Moore JP. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991;28:49-61.
6. Gondal JA, Swartz RP, Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989;33:1544-1548.
7. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ. Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet. 1992;23:279-291.
8. Ostro MJ, Cullis PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm. 1989;46:1576-1587.
9. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991;28: 83-91.
10. Schurmann D, de Matos Marques B, Grunewald T, Pohle HD, Hahn H, Ruf B. Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J Infect Dis. 1991;164:620-622.
11. Coker RJ, Viviani M, Gazzard BG, et al. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 1993; 7:829-835.
12. Ringden 0, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immuno-compromised patients. J Antimicrob Chemother. 1991;28:73-82.
13. Chopra R, Fielding A, Goldstone AH. Successful treatment of fungal infections in neutropenic patients with liposomal amphotericin (AmBisome): a report on 40 cases from a single centre. Leuk Lymphoma. 1992;7:73-77.
14. Mills W, Chopra R, Linch DC, Goldstone AW. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. BMJ. 1994;86:754-760.
15. Chopra R, Blair S. Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991;28:93-104.
16. Peterson PK, McClare P, Ramsey NKC, et al. A prospective study of infectious diseases following bone marrow transplantation: emergence of Aspergillus and cytomegalovirus as the major causes of mortality. Infect Control. 1983;4:81-89.
17. Viviani MA, Torturano AM, Pagano A, et al. European experience with itraconazole In systemic mycoses. J Am Acad Dermatol 1990;23:587-593.
18. Denning DW, Tucker RM, Hanson LH, Stevens DA. Treatment of invasive aspergillosis with itraconazole. Am J Med. 1989;86:791-800.
19. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol. 1990;23:607-614.
20. van't Wout JW, Novakova I, Verhagen CAH, Fibbe WE, de Pauw BE, van der Meer JWM. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect. 1991;22:45-52.